All In Biotech

Drug Trial Radar · NCT06747468

Avexitide for Treatment of Post-Bariatric Hypoglycemia

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Jul 8, 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Amylyx Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part open-label extension (OLE) period with a duration of approximately 32 weeks.

Conditions

  • Post Bariatric Hypoglycemia

Interventions

  • AvexitideDrug

    Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion

  • PlaceboOther

    Matching placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite rate of Level 2 and Level 3 hypoglycemic eventsTime frame: During the double-blind treatment period (approximately 16 weeks)
  2. Safety and Tolerability of avexitideTime frame: During the double-blind treatment period (approximately 16 weeks)
  3. Incidence of anti-drug antibodies (ADAb)Time frame: During the double-blind treatment period (approximately 16 weeks)

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Health Care - Endocrinology Clinic

    Stanford, California

  • University of Colorado Health Anschutz Medical Campus

    Aurora, Colorado

  • East Coast Institute for Research

    Jacksonville, Florida

  • Hanson Diabetes Center

    Port Charlotte, Florida

  • Georgia Clincal Research

    Lawrenceville, Georgia

  • Cotton-O'Neil Diabetes and Endocrinology Center

    Topeka, Kansas

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Joslin Diabetes Center

    Boston, Massachusetts

  • NYC Health + Hospitals/Queens - BRANY

    New Hyde Park, New York

  • Duke Center for Metabolic and Weight Loss Surgery

    Durham, North Carolina

  • Centricity Research Morehead City Multispecialty

    Morehead City, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Penn Medicine University City

    Philadelphia, Pennsylvania

  • Vanderbilt Weight Loss Center

    Nashville, Tennessee

  • Endocrine and Psychiatry Center

    Houston, Texas

  • Southern Endocrinology & Diabetes Associates

    Mesquite, Texas

  • UT Health San Antonio

    San Antonio, Texas

  • Diabetes and Gandular Disease Clinic

    San Antonio, Texas

  • Consano Clinical Research

    Shavano Park, Texas

  • Texas Valley Clinical Research, LLC

    Weslaco, Texas

  • UWHealth - Junction Rd Medical Center Endocrinology Clinic

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.